Recent Updates — CELU
Celularity Inc. entered into an exclusive collaboration with Vesalius Longevity Labs to provide purification, processing, and final-stage manufacturing of peptide active pharmaceutical ingredients (APIs) under the Peptual brand at its New Jersey facility. The agreement leverages Celularity's cGMP infrastructure to establish a domestic supply platform for bulk peptide material, aiming to enhance traceability and resilience amid regulatory scrutiny of imported ingredients. The partnership excludes GLP-1 receptor agonists and weight-loss peptides. This strategic move expands Celularity's contract development and manufacturing services beyond its core cell therapies into the peptide API space.
On September 29, 2026, Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors pursuant to board designation rights granted in connection with a previously announced September 2026 financing. His appointment becomes effective upon the expiration of the waiting period following the filing of an Information Statement under Section 14(f) of the Securities Exchange Act of 1934. Concurrently, Diane Parks resigned from the Board, effective at the same time, with no disagreements cited regarding operations or policies. Jain joins a newly constituted board alongside Chairman Robert J. Hariri, Peter H. Diamandis, and Philip A. Barach, bringing a consumer-focused perspective to regenerative therapies. Celularity Inc. is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta.
Celularity Inc. entered into a Securities Purchase Agreement to issue up to $25.0 million in senior secured convertible promissory notes with warrants. At the initial closing on September 24, 2026, the company raised approximately $11.01 million by issuing notes convertible at $1.50 per share into roughly 7,340,000 shares, alongside warrants for approximately 4,037,000 additional shares. The transaction includes a second tranche of up to $10.0 million available through September 2027 and amends existing debt held by the Philip & Daniele Barach Family Trust. Concurrently, Celularity settled disputes with Helena Global Investment Opportunities 1 Ltd by converting $1.197 million in principal into 700,000 shares and issuing an additional 2,000,000 shares of common stock as settlement consideration. Effective September 24, 2026, Geoffrey Ling resigned from the Board, and Philip A. Barach was appointed to replace him pursuant to a board rights agreement associated with the financing. Celularity Inc. operates in the biotechnology industry, focusing on cellular therapies for regenerative medicine.
Celularity Inc. entered into a $1,000,000 secured loan agreement with the Philip & Daniele Barach Family Trust on June 29, 2026, bearing 4.0% interest per annum, which increases to 18.0% upon default. The loan is secured by a first-priority security interest in substantially all of the Company's personal property and matures upon receipt of gross proceeds from certain financing or strategic transactions. Additionally, Vincent LeVien resigned from the Board of Directors effective June 26, 2026. Celularity Inc. is a biotechnology company focused on developing cell therapy products.
Celularity Inc. appointed Steven N. Gordon, Esq. as Chief Operating and Administrative Officer and a member of the Board of Directors, and K. Harold Fletcher, Esq. as Chief Legal and Strategy Officer and Corporate Secretary, both effective June 19, 2026. Celularity Inc. is a biotechnology company that develops and manufactures advanced cell therapy products.